Athens, Greece - A dose-response study of the ACE-inhibitor enalapril (Vasotec® - Merck) in congestive heart failure (CHF) patients found no difference in survival and clinical status in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback